University of Alabama at Birmingham to Enroll Patients in Pilot Study Using Mytrus and its iPad Application
Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that the University of Alabama at Birmingham (UAB) will use its iPad® application in an upcoming pilot study supported by the U.S. Department of Health & Human Services Agency for Healthcare Research and Quality. UAB is evaluating how digital tools might simplify enrollment and enhance patient understanding during the informed consent process. Kenneth G. Saag, MD, Msc, professor in the UAB Department of Medicine, will lead the study.
For more specific information on UAB’s usage of the Mytrus iPad application, read UAB’s article, “UAB studying high tech way to secure informed consent in research trials” by Bob Shepard, published earlier this month.
Using animation and other visual imagery, the Mytrus iPad application is the first in the industry to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only helps patients better understand the clinical trial process; it helps researchers gain valuable insight into the speed and effectiveness of the informed consent process in multi-center studies.
“The Mytrus application gives study sponsors a window into the informed consent process that they’ve never had before,” said Anthony Costello, CEO of Mytrus. “Like many sponsors we work with, the University of Alabama at Birmingham also recognizes that increasing a patient’s understanding and comfort level during consent is the best way to retain highly motivated and protocol compliant patients throughout the study.”
Related Links:
Greenphire and Mytrus Partner to Provide Web-based Solutions for Patient Recruitment and Retention
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
